Since we are playing odds, I will remind all the card holders here that character matters, and that is an important tell in my book. This is not the curious case of Dr. Jekyll and Mr. Hyde. Many here have reached out to some of the principal players such as Scott Kelly, myself included. Single word summary character judgement on my end: responsive. Ok, bonus word: compassionate. The kind of person who provides his personal cell to Doctor’s in urgent need of Leronlimab when hours can tip the scales as far as outcome. With the wall of silence only they can see the game at play, but I will wager informed by the lens of character that they are working toward our best interests.

One more tell: some here have reached out with offers with regards to private equity lifeline as needed. Again, crickets. They don’t feel the need to lay down what could be pivotal cards (yet) to take the pot or move the share price. They see things we can’t at this moment and seem to be telegraphing to shareholders that we can relax. 48 cents per share is absurd when valuing the clinical impact of this MAB; Cytodyn sees our cards and I think they would agree.

In short, Machiavelli is not guiding this company…the FUD people, short interests and greedy corporate raiders perhaps, but not Cytodyn. Longs are still in the game and with the benefit at some point of hindsight might find it hard to believe how big the pot was.